Vysis® UroVysion
Earlier detection is the key to increased survival
Detect Bladder Cancer Recurrence up to Six Months Sooner than Other Diagnostic Methods
Vysis UroVysion's molecular cytology combines the strength of urine cytology (morphology) with molecular (DNA-based) technology to unequivocally detect the presence of cancer.
- Offers greater sensitivity than tests such as cytology or biomarkers, which translates into fewer false negatives.
- Earlier detection allows you to treat your patient's cancer more aggressively as needed
- Detects high grade pT1 and pTis tumors that can be overlooked with traditional diagnostic methods and have high progression rates to muscle-invasive cancer
- Provides results you can count on – Vysis UroVysion is the first FDA-approved genomic DNA-probe test for identifying early recurrence of bladder cancer
- Not affected by BCG Immunotherapy
With Vysis UroVysion you now have a superior option to accurately manage bladder cancer recurrence.
Sensitivity
Vysis UroVysion is not only more sensitive than urine cytology by stage, but also more sensitive by grade.
Specificity
The specificity of Vysis UroVysion is approximately 95% among healthy and non-healthy subjects, which translates to fewer false positives.
Vysis UroVysion Images
 | Normal result observed in an interphase cell obtained from a sample after the Vysis UroVysion Bladder Cancer Recurrence Kit hybridization. Each probe signal, CEP 3 (red), CEP 7 (green), CEP 17 (aqua) and LSI p16 (gold) is present in two copies. |
 | Aneusomic interphase cell obtained from a sample showing two copies of chromosome 3 (red), four copies of chromosome 7 (green), five copies of chromosome 17 (aqua) and one copy of p16 gene (gold) after the Vysis UroVysion Bladder Cancer Recurrence Kit hybridization. |
Online Resources for Healthcare Professionals
- Be sure to ask your Quest Diagnostics sales representative about our new Vysis UroVysion collection kit.
- View this Vysis UroVysion information in a PDF format.
- Access our online Test Menu to obtain test ordering codes and specimen requirements.
- Visit the Hematology/Oncology section of our Test Selection and Interpretation Guide, which provides information relating to test selection, utilization, and interpretation.
- Simplify test ordering and results reporting with our connectivity solutions.
Online Test Information for Your Patients
Your patients can learn about health conditions and laboratory tests in our Patient Health Library.